FR2501505A1 - Nouveaux medicaments destines au traitement des hyperlipidemies et hypercholesterolemies a base d'acide 3,5-diiodo-3'-isopropyl-thyroacetique - Google Patents
Nouveaux medicaments destines au traitement des hyperlipidemies et hypercholesterolemies a base d'acide 3,5-diiodo-3'-isopropyl-thyroacetique Download PDFInfo
- Publication number
- FR2501505A1 FR2501505A1 FR8104834A FR8104834A FR2501505A1 FR 2501505 A1 FR2501505 A1 FR 2501505A1 FR 8104834 A FR8104834 A FR 8104834A FR 8104834 A FR8104834 A FR 8104834A FR 2501505 A1 FR2501505 A1 FR 2501505A1
- Authority
- FR
- France
- Prior art keywords
- diiodo
- isopropyl
- treatment
- thyroacetic
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title abstract description 4
- 239000003814 drug Substances 0.000 title abstract description 3
- 239000002253 acid Substances 0.000 abstract description 10
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 4
- 208000008589 Obesity Diseases 0.000 abstract description 4
- 235000020824 obesity Nutrition 0.000 abstract description 4
- 239000013543 active substance Substances 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 description 14
- 241000700159 Rattus Species 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000002547 new drug Substances 0.000 description 7
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- KSZBMSJSJFZGRF-UHFFFAOYSA-N 2-[4-(4-hydroxy-3-propan-2-ylphenoxy)-3,5-diiodophenyl]acetic acid Chemical compound C1=C(O)C(C(C)C)=CC(OC=2C(=CC(CC(O)=O)=CC=2I)I)=C1 KSZBMSJSJFZGRF-UHFFFAOYSA-N 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000011680 zucker rat Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8104834A FR2501505A1 (fr) | 1981-03-11 | 1981-03-11 | Nouveaux medicaments destines au traitement des hyperlipidemies et hypercholesterolemies a base d'acide 3,5-diiodo-3'-isopropyl-thyroacetique |
| CH142582A CH652925A5 (fr) | 1981-03-11 | 1982-03-09 | Medicaments destines au traitement de l'obesite des hyperlipidemies et hypercholesterolemies. |
| EP82400431A EP0060776B1 (fr) | 1981-03-11 | 1982-03-10 | Médicaments déstinés au traitement de l'obésité et des hyperlipidémies |
| DE8282400431T DE3264378D1 (en) | 1981-03-11 | 1982-03-10 | Medicaments for the treatment of obesity and hyperlipoidemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8104834A FR2501505A1 (fr) | 1981-03-11 | 1981-03-11 | Nouveaux medicaments destines au traitement des hyperlipidemies et hypercholesterolemies a base d'acide 3,5-diiodo-3'-isopropyl-thyroacetique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2501505A1 true FR2501505A1 (fr) | 1982-09-17 |
| FR2501505B1 FR2501505B1 (enExample) | 1984-01-20 |
Family
ID=9256100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8104834A Granted FR2501505A1 (fr) | 1981-03-11 | 1981-03-11 | Nouveaux medicaments destines au traitement des hyperlipidemies et hypercholesterolemies a base d'acide 3,5-diiodo-3'-isopropyl-thyroacetique |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0060776B1 (enExample) |
| CH (1) | CH652925A5 (enExample) |
| DE (1) | DE3264378D1 (enExample) |
| FR (1) | FR2501505A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284971A (en) * | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
| US5827734A (en) * | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5858967A (en) * | 1995-01-20 | 1999-01-12 | University Of Washington | Appetite supression factor and related methods |
| US6380255B1 (en) | 1995-06-07 | 2002-04-30 | Karo Bio Ab | Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds |
| ES2208753T5 (es) * | 1995-06-07 | 2009-02-01 | Lavin, Dr., Thomas N. | Nuevos usos para las hormonas tiroideas o compuestos del tipo de hormona tiroidea. |
| ITRM20030363A1 (it) * | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
| US20060292194A1 (en) * | 2005-06-24 | 2006-12-28 | Thomas Lavin | Treatment for burns and adipose deposits using thyroid hormone compound in a human |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1227221A (fr) * | 1957-08-21 | 1960-08-19 | Hoechst Ag | Acides phénoxy-phénylacétiques iodés et leur préparation |
| GB994611A (en) * | 1962-12-03 | 1965-06-10 | Upjohn Co | Improvements in or relating to therapeutically active iodine-substituted aromatic compounds and compositions containing them |
| US3210413A (en) * | 1962-05-17 | 1965-10-05 | Smith Kline French Lab | Antihypercholesterolemic agents |
-
1981
- 1981-03-11 FR FR8104834A patent/FR2501505A1/fr active Granted
-
1982
- 1982-03-09 CH CH142582A patent/CH652925A5/fr not_active IP Right Cessation
- 1982-03-10 DE DE8282400431T patent/DE3264378D1/de not_active Expired
- 1982-03-10 EP EP82400431A patent/EP0060776B1/fr not_active Expired
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1227221A (fr) * | 1957-08-21 | 1960-08-19 | Hoechst Ag | Acides phénoxy-phénylacétiques iodés et leur préparation |
| US3210413A (en) * | 1962-05-17 | 1965-10-05 | Smith Kline French Lab | Antihypercholesterolemic agents |
| GB994611A (en) * | 1962-12-03 | 1965-06-10 | Upjohn Co | Improvements in or relating to therapeutically active iodine-substituted aromatic compounds and compositions containing them |
Non-Patent Citations (2)
| Title |
|---|
| CA1964 * |
| EXBK/63 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0060776A1 (fr) | 1982-09-22 |
| EP0060776B1 (fr) | 1985-06-26 |
| DE3264378D1 (en) | 1985-08-01 |
| CH652925A5 (fr) | 1985-12-13 |
| FR2501505B1 (enExample) | 1984-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8741364B2 (en) | Method of improving fat metabolism | |
| TWI361076B (en) | Composition containing extract of aframomum melegueta | |
| US5262162A (en) | Cerebral-activating extract | |
| US8105637B2 (en) | Composition comprising nanoparticle Ginkgo biloba extract with the effect of brain function activation | |
| FR2501505A1 (fr) | Nouveaux medicaments destines au traitement des hyperlipidemies et hypercholesterolemies a base d'acide 3,5-diiodo-3'-isopropyl-thyroacetique | |
| CA2890386A1 (en) | Blood flow promoting agent | |
| EP2217255B1 (fr) | Utilisation de phytoecdysones dans la preparation d'une composition pour agir sur le syndrome metabolique | |
| JPH023495A (ja) | 抗酸化剤 | |
| JP4122156B2 (ja) | ビシナルジチオグリコールを含む生理活性物質および様々な経済分野でのその利用 | |
| CA2567479C (fr) | Utilisation d'alkyle furannes pour la preparation d'un medicament destine au traitement de l'obesite et pour le traitement cosmetique de la surcharge ponderale | |
| EP2726087A1 (fr) | Compositions pour le traitement ou la prévention du cancer de la prostate à base d'extrait de graines de brocoli | |
| JPH11180869A (ja) | 血中脂質改善剤、サイクリックａｍｐホスホジエステラーゼ阻害剤、飲食品および皮膚外用剤 | |
| EP2819635B1 (fr) | Produit de combinaison pour le traitement du surpoids et/ou l'amélioration de la silhouette | |
| KR101721022B1 (ko) | 아디프산을 유효성분으로 함유하는 피부주름개선 및 피부탄력증진용 조성물 | |
| CA2693807A1 (fr) | Composition alimentaire pour ameliorer la digestibilite des lipides alimentaires | |
| CA2566970C (fr) | Utilisation d'alkyle furannes pour la preparation d'un medicament destine au traitement du diabete | |
| KR20220100260A (ko) | 항염증 활성을 갖는 폴리아민 고함유 고추 추출물의 유효 추출 방법 | |
| CA2909750C (fr) | Composition pharmaceutique, dietetique ou alimentaire liquide ou semi-liquide depourvue d'amertume contenant un sel d'arginine | |
| FR2828379A1 (fr) | Composition nutritive a base de cortex de cabosse, procede de preparation et utilisation notamment en alimentation et cosmetique | |
| RU2616248C2 (ru) | Композиции для местного применения, содержащие диаминоксидазу, для лечения или предотвращения заболеваний, связанных с высокими уровнями гистамина, сопровождаемых усилением боли | |
| EP1753391B1 (fr) | Utilisation d'alkyle furannes pour le traitement cosmetique de la cellulite | |
| BE1027552B1 (fr) | Composition du ginseng et son utilisation comme medicament pour le traitement ou la prevention du stress | |
| EP4151203A1 (fr) | Extrait de tourteau de colza, procédé de préparation et utilisation en cosmétique notamment en tant qu agent propigmentant, amincissant | |
| EP4281067A1 (fr) | Procede d'amelioration de l'activite antioxydante de la vitamine c en solution aqueuse | |
| WO2024231160A1 (fr) | Composition pharmaceutique ou cosmétique favorisant la croissance des cheveux |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |